Bristol-Myers: It’s Worth the Premium, Leerink Says
December 31, 2015 at 12:58 PM EST
Of the 21 drug makers in the S&P 500 index, Bristol-Myers Squibb ( BMY ) ends 2015 as one of the group’s strongest performing stocks. It is also one of the most expensive drug makers in the index, trading at more than 30 times 2016 earnings estimates. But according to Leerink analyst Seamus Fernandez and his team, Bristol is worth that premium. READ MORE »